Stocks to Watch - AFLB, CYPB, AMTD

A5 Laboratories Inc. (A5 Labs) (OTCBB: AFLB) $0.92. Today announced that it has signed an analytical services contract with BioActif Inc. of Blainville, Quebec. Upon obtaining health Canada laboratory establishment license, A5 Labs will provide a comprehensive analytical and development services for BioActif. These services will include method development, raw materials and finished goods testing as well as stability studies.

"We are extremely pleased to have reached this agreement with such prestigious brand company such as BioActif. BioActif's selection of our services is a terrific endorsement of our capabilities including complex analytical procedures and stability studies, and it is another significant step in establishing A5 Labs as a premium world class CRO and Biotechnology company," said Dr. Richard Azani, President and CEO.

What They Do: A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.

To learn more about AFLB visit http://www.smallcapreview.com/.

Cypress Bioscience, Inc. (Nasdaq: CYPB) $3.35 Today announced that it has received an unsolicited proposal from Ramius LLC ("Ramius") to acquire the Company for $4.00 per share in cash. Cypress's Board of Directors will review the proposal with its financial and legal advisors. Cypress's stockholders are advised to take no action at this time.

What They Do: Cypress Bioscience, Inc develops and commercializes therapeutics and personalized medicine services to facilitate improved and individualized patient care. Cypress' goal is to address the evolving needs of specialist physicians and their patients by identifying unmet medical needs in the areas of pain, rheumatology, and central nervous system disorders, including challenging disorders such as fibromyalgia, rheumatoid arthritis, lupus and, with the license agreement with BioLineRx, schizophrenia.

TD Ameritrade (Nasdaq: AMTD) $15.82. Today announced it has released results for the third quarter of fiscal 2010. The Company continues to execute on its organic growth strategy, with record average trades per day and a double-digit annualized net new asset growth rate. The Company’s results for the quarter ended June 30, 2010 include the following (year-over-year comparisons):

• Net income of $179 million, or $0.30 per diluted share
• Net new client assets of $8.9 billion, an increase of 29 percent year-over-year, an annualized growth rate of 10 percent of beginning client assets
• Record average client trades per day of approximately 413,000, an increase of 6 percent
• Gross new accounts of approximately 175,000, virtually flat with the June 2009 quarter
• Record net revenues of $692 million, 47 percent of which were asset-based
• Operating income of $300 million, or 43 percent of net revenues
• Pre-tax income of $289 million, or 42 percent of net revenues
• EBITDA of $340 million, or 49 percent of net revenues⁽²⁾
• Liquid assets of $1.2 billion⁽²⁾; cash and cash equivalents of $716 million
• Record interest rate sensitive assets of $63.2 billion, up 13 percent⁽³⁾
• Client assets of approximately $324 billion, an increase of 22 percent

What They Do: TD AMERITRADE Holding Corporation, through its brokerage subsidiaries,combines innovative trading technology, easy-to-use and understand trading tools, investment services, investor education and superior client service to create a market-leading financial services experience.

Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.

No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. SmallCapReview has been compensated five thousand dollars for its efforts with regards to A5 Laboratories by a third party AWT.

Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/.